International Journal for Doctor of Medicine and  Medical Students (IJDMMS)

Abstract

Gynecological cancers including cervical, ovarian, endometrial, vaginal, and vulvar cancers represent a major global health burden among women. These malignancies vary significantly in incidence, etiology, clinical presentation, and prognosis. Advances in screening, molecular diagnostics, and treatment strategies have improved survival outcomes, yet disparities remain, particularly in low- and middle-income countries. This article reviews the epidemiology, risk factors, diagnostic approaches, and current management of gynecological cancers, emphasizing the importance of early detection and multidisciplinary care.

Introduction

Gynecological cancers are malignancies originating in the female reproductive system, primarily affecting the cervix, ovaries, uterus, vagina, and vulva. Among these, cervical cancer remains the most common in developing countries, while endometrial cancer predominates in developed regions [1,2]. Ovarian cancer, although less common, is associated with high mortality due to late diagnosis [3].

The etiology of gynecological cancers involves genetic, hormonal, infectious, and environmental factors. Persistent infection with high-risk human papillomavirus (HPV) is the primary cause of cervical cancer [4]. Meanwhile, genetic mutations such as BRCA1/2 significantly increase ovarian cancer risk [5].

Despite advances in screening and treatment, these cancers continue to pose challenges due to late presentation, limited awareness, and healthcare inequalities [6].

Methods

This article is a narrative review based on published literature from databases such as PubMed, WHO reports, and oncology guidelines. Relevant studies published between 2000 and 2025 were selected, focusing on epidemiology, diagnosis, and treatment of gynecological cancers. Keywords included “gynecological cancers,” “cervical cancer,” “ovarian cancer,” “endometrial cancer,” “screening,” and “oncology management.”

Results

1. Epidemiology

• Cervical cancer is the fourth most common cancer in women globally [1].

• Ovarian cancer has the highest mortality among gynecological malignancies [3].

• Endometrial cancer incidence is rising due to obesity and aging populations [7].

2. Risk Factors

• Cervical cancer: HPV infection, early sexual activity, multiple partners [4].

• Ovarian cancer: BRCA mutations, nulliparity, family history [5].

• Endometrial cancer: obesity, estrogen exposure, diabetes [8].

3. Clinical Presentation

• Abnormal vaginal bleeding is common in cervical and endometrial cancers [9].

• Ovarian cancer often presents with vague symptoms such as bloating and abdominal pain [10].

4. Diagnosis

• Screening: Pap smear and HPV testing for cervical cancer [11].

• Imaging: Ultrasound, CT, MRI for tumor evaluation [12].

• Biopsy: gold standard for definitive diagnosis [13].

• Tumor markers: CA-125 for ovarian cancer [14].

5. Treatment

• Surgery: primary treatment for most gynecological cancers [15].

• Radiotherapy: commonly used in cervical cancer [16].

• Chemotherapy: platinum-based regimens for ovarian cancer [17].

• Targeted therapy: PARP inhibitors in BRCA-mutated ovarian cancer [18].

• Immunotherapy: emerging role in advanced cancers [19].

Discussion

Gynecological cancers remain a major public health issue, particularly in resource-limited settings. Cervical cancer is largely preventable through HPV vaccination and screening, yet access remains uneven [20]. Ovarian cancer continues to have poor outcomes due to lack of effective early detection methods.

Recent advances in molecular biology have improved understanding of tumor behavior, leading to targeted therapies and personalized medicine approaches. However, challenges such as late diagnosis, treatment resistance, and healthcare disparities persist.

A multidisciplinary approach involving gynecologists, oncologists, radiologists, and pathologists is essential for optimal management. Public health strategies focusing on awareness, vaccination, and screening are critical for reducing disease burden.

Conclusion

Gynecological cancers encompass a diverse group of malignancies with varying clinical and biological characteristics. Early detection, improved screening programs, and advancements in treatment have significantly enhanced patient outcomes. Continued research and global health initiatives are necessary to address disparities and improve survival rates worldwide.

References

1. Sung H, et al. Global cancer statistics 2020. CA Cancer J Clin. 2021.

2. Bray F, et al. Global cancer patterns. Lancet. 2018.

3. Torre LA, et al. Ovarian cancer statistics. CA Cancer J Clin. 2018.

4. Walboomers JM, et al. HPV and cervical cancer. J Pathol. 1999.

5. King MC, et al. BRCA genes and cancer risk. Science. 2003.

6. WHO. Cancer control programs. 2020.

7. Lortet-Tieulent J, et al. Endometrial cancer trends. Int J Cancer. 2018.

8. Kaaks R, et al. Obesity and endometrial cancer. Lancet Oncol. 2002.

9. Berek JS. Gynecologic oncology. 2019.

10. Reid BM, et al. Ovarian cancer symptoms. Int J Gynecol Cancer. 2017.

11. Arbyn M, et al. Cervical screening guidelines. BMJ. 2020.

12. Sala E, et al. Imaging in gynecologic oncology. Radiology. 2013.

13. Kurman RJ. Pathology of gynecologic cancers. 2014.

14. Bast RC Jr, et al. CA-125 and ovarian cancer. N Engl J Med. 1983.

15. du Bois A, et al. Surgery in ovarian cancer. Ann Oncol. 2009.

16. Chemoradiotherapy for cervical cancer. Lancet. 1999.

17. Armstrong DK, et al. Chemotherapy in ovarian cancer. J Clin Oncol. 2006.

18. Lord CJ, Ashworth A. PARP inhibitors. Science. 2017.

19. Marabelle A, et al. Immunotherapy in cancer. Nat Rev Clin Oncol. 2020.

20. WHO. HPV vaccination strategy. 2020.